HOME >> BIOLOGY >> NEWS
Vion's TAPET® administered to first patients in Phase I human intratumoral safety trial at the Cleveland Clinic Foundation

NEW HAVEN, CONN., DECEMBER 8, 1999 -- VION PHARMACEUTICALS, INC. (NASDAQ NM: VION) today announced that VNP20009, the company's first generation TAPET® bacterial vector, has been administered to the first patients enrolled into Vion's Phase I intratumoral trial, which is being conducted at The Cleveland Clinic Foundation. The patients were initially monitored in the hospital and subsequently discharged. Potential safety and efficacy will continue to be monitored according to the protocol. The Phase I study is designed to evaluate the safety, potential efficacy and optimum biological dose of an intratumoral administration for patients with either cutaneous or subcutaneous solid tumors. Patients will be evaluated for the accumulation of VNP20009 in the tumor and non-injected lesions. Patient accrual continues for this trial, which may involve up to 20-30 patients.

TAPET (Tumor Amplified Protein Expression Therapy), Vion's core platform technology, are highly attenuated bacteria that, in preclinical studies, have demonstrated preferential replication in tumors compared to normal tissues. The bioengineered bacteria have demonstrated an excellent safety profile in preclinical toxicology studies. Preferential replication allows the bacteria to produce and deliver a variety of anti-cancer therapeutic products at high concentrations to tumors while minimizing toxicity to normal tissues. By bringing the "drug factory" preferentially to the tumor, Vion believes that TAPET may result in a cancer therapy that is more concentrated, more effective and less toxic to normal tissue. Furthermore, the unarmed bacteria by themselves have shown good anti-tumor activity in animal models. Vion plans to develop the unarmed TAPET alone as an anti-tumor agent and to develop second-generation products that produce and deliver potent therapeutic anti-cancer agents.

Vion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the research, development and commerci
'"/>

Contact: Sue Yeoh
syeoh@cpronline.com
201-641-2408 x43
Vion Pharmaceuticals, Inc.
8-Dec-1999


Page: 1 2

Related biology news :

1. Vions TAPET Organisms Demonstrate Reduced Virulence, Increased Safety While Retaining Ability To Specifically Target Tumors
2. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
3. Newly identified master gene key in babys first breath
4. The book opens on the first tree genome
5. DuPont developing new protective suits for military, first responders
6. Joslin Diabetes Center adds first affiliate in California at Irvine Medical Center
7. Maine-based biophysics institute gets funding for first US-based 4Pi nanoscale microscope
8. Veterinarians discover first known case of canine distemper in a wild tiger
9. Study reveals first genetic step necessary for prostate cancer growth
10. The first engineering of cell surfaces in living animals
11. Infant rats eagerly accept high concentrations of alcohol upon first exposure

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/4/2019)... , ... June 04, 2019 , ... ... of orthopedic medical devices, today announced Q1-19 revenues of $31M, up 12% from ... with successful roll-out of strategic investments & operational excellence initiatives worldwide. , ...
(Date:6/4/2019)... ... ... Lajollacooks4u is delighted to announce it has been named as one of ... only to businesses that have achieved consistently outstanding traveler reviews on TripAdvisor, as well ... qualify for the Certificate of Excellence –- an award that only 10 percent of ...
(Date:5/31/2019)... , ... May 30, 2019 , ... ... testing company, and Mayo Clinic, have documented significant differences in the prevalence of ... and ethnic populations compared to non-Hispanic White women. Results will be presented at ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... ... May 30, 2019 , ... A study ... efficient delivery system for the sustained release of human placental stem cell (HPSC)-derived ... was able to deliver CM into the injured kidney, where it helped restore ...
(Date:5/15/2019)... ... 15, 2019 , ... Milton Hershey School® has named William Charles Ballough Harding ... biomedical industry, where he is changing lives by creating solutions to global healthcare challenges ... the vision of our founders – Milton and Catherine Hershey – who always hoped ...
(Date:5/14/2019)... LA JOLLA, Calif. (PRWEB) , ... May 14, 2019 , ... ... announces an office expansion, effectively doubling its space from 2,500 to 5,000 square feet. ... SneakPeek Early Gender DNA tests ,” says Gateway Genomics CEO, Chris Jacob. “The ...
(Date:5/4/2019)... Brazil (PRWEB) , ... May 03, 2019 , ... ... given by the President of the Dakila Pesquisas Association, the scientist and ufologist ... Councilmen 2019, in Brasília (DF). Urandir detailed the results of some research carried ...
Breaking Biology Technology:
Cached News: